Shares of Kintara Therapeutics, Inc. (NASDAQ:KTRA) traded up 14.3% during trading on Thursday . The company traded as high as $1.83 and last traded at $1.60. 966,016 shares were traded during mid-day trading, an increase of 67% from the average session volume of 576,990 shares. The stock had previously closed at $1.40.
Separately, Aegis started coverage on shares of Kintara Therapeutics in a research report on Monday, September 14th. They set a “buy” rating and a $6.00 target price on the stock.
The stock has a market cap of $37.67 million, a P/E ratio of -1.20 and a beta of 2.00.
Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Its product candidate is VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma.
Read More: Dividend
Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.